Methotrexate-induced papular eruption: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Infobox medical condition | |||
| name = Methotrexate-induced papular eruption | |||
| synonyms = | |||
| field = [[Dermatology]] | |||
| symptoms = [[Papule]]s, [[rash]], [[pruritus]] | |||
| complications = | |||
| onset = | |||
| duration = | |||
| causes = [[Methotrexate]] | |||
| risks = | |||
| diagnosis = Clinical evaluation, [[skin biopsy]] | |||
| differential = [[Drug eruption]], [[psoriasis]], [[eczema]] | |||
| prevention = | |||
| treatment = Discontinuation of methotrexate, [[topical corticosteroids]] | |||
| medication = | |||
| prognosis = | |||
| frequency = Rare | |||
| deaths = | |||
}} | |||
{{Short description|A skin condition caused by methotrexate}} | {{Short description|A skin condition caused by methotrexate}} | ||
==Methotrexate-induced papular eruption== | ==Methotrexate-induced papular eruption== | ||
'''Methotrexate-induced papular eruption''' is a [[dermatological]] condition characterized by the appearance of papules on the skin as a result of [[methotrexate]] therapy. Methotrexate is a [[disease-modifying antirheumatic drug]] (DMARD) commonly used in the treatment of various [[autoimmune diseases]] and certain types of [[cancer]]. | '''Methotrexate-induced papular eruption''' is a [[dermatological]] condition characterized by the appearance of papules on the skin as a result of [[methotrexate]] therapy. Methotrexate is a [[disease-modifying antirheumatic drug]] (DMARD) commonly used in the treatment of various [[autoimmune diseases]] and certain types of [[cancer]]. | ||
==Pathophysiology== | ==Pathophysiology== | ||
Methotrexate works by inhibiting the enzyme [[dihydrofolate reductase]], which is crucial for the synthesis of [[nucleotides]] and, consequently, [[DNA]] replication and cell division. This mechanism is beneficial in slowing down the rapid proliferation of cells in conditions like [[psoriasis]] and certain cancers. However, it can also affect normal skin cells, leading to adverse dermatological reactions such as papular eruptions. | Methotrexate works by inhibiting the enzyme [[dihydrofolate reductase]], which is crucial for the synthesis of [[nucleotides]] and, consequently, [[DNA]] replication and cell division. This mechanism is beneficial in slowing down the rapid proliferation of cells in conditions like [[psoriasis]] and certain cancers. However, it can also affect normal skin cells, leading to adverse dermatological reactions such as papular eruptions. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
Patients with methotrexate-induced papular eruption typically present with small, raised, red or skin-colored papules. These lesions are often distributed symmetrically and can appear on the [[trunk]], [[extremities]], and occasionally on the [[face]]. The papules may be accompanied by [[pruritus]] (itching) and can vary in number and size. | Patients with methotrexate-induced papular eruption typically present with small, raised, red or skin-colored papules. These lesions are often distributed symmetrically and can appear on the [[trunk]], [[extremities]], and occasionally on the [[face]]. The papules may be accompanied by [[pruritus]] (itching) and can vary in number and size. | ||
==Diagnosis== | ==Diagnosis== | ||
The diagnosis of methotrexate-induced papular eruption is primarily clinical, based on the patient's history of methotrexate use and the characteristic appearance of the skin lesions. A [[skin biopsy]] may be performed to rule out other conditions and to confirm the diagnosis. Histopathological examination typically shows features of a drug-induced eruption, such as [[lymphocytic infiltrate]] and [[epidermal]] changes. | The diagnosis of methotrexate-induced papular eruption is primarily clinical, based on the patient's history of methotrexate use and the characteristic appearance of the skin lesions. A [[skin biopsy]] may be performed to rule out other conditions and to confirm the diagnosis. Histopathological examination typically shows features of a drug-induced eruption, such as [[lymphocytic infiltrate]] and [[epidermal]] changes. | ||
==Management== | ==Management== | ||
Management of methotrexate-induced papular eruption involves discontinuation or adjustment of methotrexate therapy. In some cases, reducing the dose or switching to an alternative medication may be necessary. Topical treatments, such as [[corticosteroids]], can be used to alleviate symptoms. In severe cases, systemic treatments may be required. | Management of methotrexate-induced papular eruption involves discontinuation or adjustment of methotrexate therapy. In some cases, reducing the dose or switching to an alternative medication may be necessary. Topical treatments, such as [[corticosteroids]], can be used to alleviate symptoms. In severe cases, systemic treatments may be required. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for methotrexate-induced papular eruption is generally good, especially if the offending drug is discontinued or the dose is adjusted. The skin lesions typically resolve without scarring once methotrexate is withdrawn or the dose is reduced. | The prognosis for methotrexate-induced papular eruption is generally good, especially if the offending drug is discontinued or the dose is adjusted. The skin lesions typically resolve without scarring once methotrexate is withdrawn or the dose is reduced. | ||
==Prevention== | ==Prevention== | ||
Preventive measures include careful monitoring of patients on methotrexate therapy, especially those with a history of drug-induced skin reactions. Regular follow-up and patient education about potential side effects can help in early detection and management of adverse reactions. | Preventive measures include careful monitoring of patients on methotrexate therapy, especially those with a history of drug-induced skin reactions. Regular follow-up and patient education about potential side effects can help in early detection and management of adverse reactions. | ||
==Related pages== | ==Related pages== | ||
* [[Methotrexate]] | * [[Methotrexate]] | ||
| Line 34: | Line 39: | ||
* [[Psoriasis]] | * [[Psoriasis]] | ||
* [[Autoimmune disease]] | * [[Autoimmune disease]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Adverse drug reactions]] | [[Category:Adverse drug reactions]] | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
Latest revision as of 00:11, 4 April 2025
| Methotrexate-induced papular eruption | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Papules, rash, pruritus |
| Complications | |
| Onset | |
| Duration | |
| Types | N/A |
| Causes | Methotrexate |
| Risks | |
| Diagnosis | Clinical evaluation, skin biopsy |
| Differential diagnosis | Drug eruption, psoriasis, eczema |
| Prevention | |
| Treatment | Discontinuation of methotrexate, topical corticosteroids |
| Medication | |
| Prognosis | |
| Frequency | Rare |
| Deaths | |
A skin condition caused by methotrexate
Methotrexate-induced papular eruption[edit]
Methotrexate-induced papular eruption is a dermatological condition characterized by the appearance of papules on the skin as a result of methotrexate therapy. Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used in the treatment of various autoimmune diseases and certain types of cancer.
Pathophysiology[edit]
Methotrexate works by inhibiting the enzyme dihydrofolate reductase, which is crucial for the synthesis of nucleotides and, consequently, DNA replication and cell division. This mechanism is beneficial in slowing down the rapid proliferation of cells in conditions like psoriasis and certain cancers. However, it can also affect normal skin cells, leading to adverse dermatological reactions such as papular eruptions.
Clinical Presentation[edit]
Patients with methotrexate-induced papular eruption typically present with small, raised, red or skin-colored papules. These lesions are often distributed symmetrically and can appear on the trunk, extremities, and occasionally on the face. The papules may be accompanied by pruritus (itching) and can vary in number and size.
Diagnosis[edit]
The diagnosis of methotrexate-induced papular eruption is primarily clinical, based on the patient's history of methotrexate use and the characteristic appearance of the skin lesions. A skin biopsy may be performed to rule out other conditions and to confirm the diagnosis. Histopathological examination typically shows features of a drug-induced eruption, such as lymphocytic infiltrate and epidermal changes.
Management[edit]
Management of methotrexate-induced papular eruption involves discontinuation or adjustment of methotrexate therapy. In some cases, reducing the dose or switching to an alternative medication may be necessary. Topical treatments, such as corticosteroids, can be used to alleviate symptoms. In severe cases, systemic treatments may be required.
Prognosis[edit]
The prognosis for methotrexate-induced papular eruption is generally good, especially if the offending drug is discontinued or the dose is adjusted. The skin lesions typically resolve without scarring once methotrexate is withdrawn or the dose is reduced.
Prevention[edit]
Preventive measures include careful monitoring of patients on methotrexate therapy, especially those with a history of drug-induced skin reactions. Regular follow-up and patient education about potential side effects can help in early detection and management of adverse reactions.
